ArticleVaccine2009
A novel chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines.
Article in Vaccine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02485912 (A Phase Ib Safety and Immunogenicity Clinical Trial of Heterologous Prime-boost Immunisation With ChAd3-EBO Z and MVA-EBO Z in Healthy Senegalese Adult Volunteers Aged 18-50 Years.), which is not on this map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase Ib Safety and Immunogenicity Clinical Trial of Heterologous Prime-boost Immunisation With ChAd3-EBO Z and MVA-EBO Z in Healthy Senegalese Adult Volunteers Aged 18-50 Years.
Who cites it
25 citing papers in PubMed, 53 citations in OpenAlex.
- A data-driven cartography of NSCLC vaccine research: Quantifying the paradigm shift toward immuno-oncology combination therapies.Human vaccines & immunotherapeutics · 2026Review
- Article
- One HA stalk topping multiple heads as a novel influenza vaccine.Emerging microbes & infections · 2024Article
- Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial.Lancet (London, England) · 2023Article
- Novel and efficient method for the reconstruction of adenoviruses through isothermal assembly and its potential applications.Frontiers in medical technology · 2023Article
- Understanding Post Entry Sorting of Adenovirus Capsids; A Chance to Change Vaccine Vector Properties.Viruses · 2021Review
- Article
- Development of novel vaccine vectors: Chimpanzee adenoviral vectors.Human vaccines & immunotherapeutics · 2018Review
- Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.Vaccine · 2016Article
- Analysis of T cell responses to chimpanzee adenovirus vectors encoding HIV gag-pol-nef antigen.Vaccine · 2015Article
- Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling.The Journal of clinical investigation · 2015Article
- Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- Article
- Gene therapy for lung cancer malignant pleural effusion: current and future nano-biotechnology.Translational lung cancer research · 2012Article
- Management of malignant pleural effusion by suicide gene therapy in advanced stage lung cancer: a case series and literature review.Cancer gene therapy · 2012Review
- Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates.Journal of virology · 2012Article
- T-cell-inducing vaccines - what's the future.Immunology · 2012Review
- Article
- Advances and future challenges in adenoviral vector pharmacology and targeting.Current gene therapy · 2011Review
- Nanoparticle delivery systems in cancer vaccines.Pharmaceutical research · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of adenovirus (Ad) as vaccine vectors is hindered by pre-existing immunity to human Ads in most of the human population. In order to overcome this limitation, uncommon alternative Ad serotypes need to be utilized. In this study, an E1-E3 deleted recombinant Ad based on the chimpanzee serotype 3 (ChAd3) was engineered to express human carcinoembryonic antigen (CEA) protein or rat neu extracellular/transmembrane domains (ECD.TM). ChAd3 vectors were tested in CEA transgenic (CEA.Tg) and BALB/NeuT mice, which show immunologic tolerance to these antigens. ChAd3 is capable of inducing an immune response comparable to that of hAd5 serotype-based vectors, thus breaking tolerance to tumor associated antigens (TAAs) and achieving anti-tumor effects. Of importance is that ChAd3 can overcome hAd5 pre-existing immunity and work in conjunction with DNA electroporation (DNA-EP) and other Ad vaccines based on common human serotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.